Overview

A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
To assess the safety and efficacy of SU011248 in patients with metastatic, refractory renal cell carcinoma
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Sunitinib